Non-thromboembolic risk in systemic lupus erythematosus associated with antiphospholipid syndrome

ObjectivesWe investigated the impact of secondary antiphospholipid syndrome (APS) and antiphospholipid antibody (aPL) positivity on the non-thromboembolic clinical manifestations of systemic lupus erythematosus (SLE).MethodsIn total, 224 patients with SLE were studied, of whom 105 were aPL-positive;...

Full description

Saved in:
Bibliographic Details
Main Authors: Deák Magdolna
Bocskai Márta
Burcsár Szilárd
Dányi O.
Fekete Z.
Kovács László
Format: Article
Published: 2014
Series:LUPUS 23 No. 9
doi:10.1177/0961203314531839

mtmt:2601977
Online Access:http://publicatio.bibl.u-szeged.hu/9665
Description
Summary:ObjectivesWe investigated the impact of secondary antiphospholipid syndrome (APS) and antiphospholipid antibody (aPL) positivity on the non-thromboembolic clinical manifestations of systemic lupus erythematosus (SLE).MethodsIn total, 224 patients with SLE were studied, of whom 105 were aPL-positive; 52 fulfilled the criteria for APS. SLE- and APS-related clinical and laboratory features were assesed: SLE patients with aPL or APS were compared with those without these features.ResultsNot only thromboembolic events, but also Coombs-positive haemolytic anaemia, thrombocytopenia and endocarditis occurred significantly more frequently in the aPL-positive than in the aPL-negative patients. In the APS + SLE subgroup, several non-thromboembolic symptoms occurred more often than in the absence of APS: pleuritis, interstitial lung disease, myocarditis, nephritis and organic brain syndrome. The mean number of major organ manifestations (1.2 vs. 0.5) and the overall number of organ manifestations (8.1 vs. 6.9) were higher in the APS + SLE patients than in those without APS (p < 0.05). The APS + SLE subgroup more frequently required intensive immunosuppressive treatment than did the APS-negative patients (p < 0.05).ConclusionsSLE patients with aPL positivity or secondary APS also have a higher risk to develop non-thromboembolic disease manifestations in addition to the aPL-related symptoms, and are predisposed to more severe SLE manifestations.
Physical Description:913-918
ISSN:0961-2033